科拓生物
(300858)
| 流通市值：30.21亿 | | | 总市值：44.48亿 |
| 流通股本：1.79亿 | | | 总股本：2.63亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,025,584.73 | 299,241,834.45 | 216,946,877.08 | 139,931,675.55 |
| 营业收入 | 59,025,584.73 | 299,241,834.45 | 216,946,877.08 | 139,931,675.55 |
| 二、营业总成本 | 40,467,617.52 | 209,600,910.79 | 148,503,966.53 | 103,237,998.13 |
| 营业成本 | 26,952,626.55 | 135,909,713.8 | 99,383,918.68 | 67,267,594.36 |
| 税金及附加 | 587,988.5 | 4,918,248.77 | 3,173,889.38 | 2,729,022.63 |
| 销售费用 | 5,462,498.53 | 33,937,227.05 | 23,081,290.58 | 16,476,938.04 |
| 管理费用 | 6,321,141.44 | 24,097,003.54 | 14,869,701.65 | 12,620,790.29 |
| 研发费用 | 8,008,843.89 | 34,194,078.64 | 24,693,697.74 | 15,121,654.37 |
| 财务费用 | -6,865,481.39 | -23,455,361.01 | -16,698,531.5 | -10,978,001.56 |
| 其中:利息费用 | 205,016.98 | 500,914.39 | 283,524.34 | 225,279.23 |
| 其中:利息收入 | 7,078,660.74 | 24,003,601.93 | 17,103,724.52 | 11,225,805.45 |
| 加:公允价值变动收益 | 1,134,383.57 | 1,262,328.77 | 1,535,547.95 | 2,094,676.99 |
| 加:投资收益 | 280,184.64 | 6,122,192.73 | 5,193,747.22 | 2,140,299.56 |
| 资产处置收益 | 568,552.16 | 34,002.85 | -22,030.7 | -22,030.7 |
| 信用减值损失(新) | -215,116.49 | -1,818,460.45 | -3,033,080.75 | -1,797,475.85 |
| 其他收益 | 1,897,730.53 | 7,360,708.72 | 7,053,352.77 | 6,276,885.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,223,701.62 | 102,601,696.28 | 79,170,447.04 | 45,386,032.7 |
| 加:营业外收入 | 4,691.54 | 27,126.95 | 19,479.19 | 16,476.65 |
| 减:营业外支出 | 2,055.85 | 587,787.2 | 413,382.96 | 413,341.91 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,226,337.31 | 102,041,036.03 | 78,776,543.27 | 44,989,167.44 |
| 减:所得税费用 | 3,709,892.48 | 8,561,127.03 | 6,770,957.1 | 4,656,570.77 |
| 六、净利润 | 18,516,444.83 | 93,479,909 | 72,005,586.17 | 40,332,596.67 |
| 持续经营净利润 | 18,516,444.83 | 93,479,909 | 72,005,586.17 | 40,332,596.67 |
| 归属于母公司股东的净利润 | 18,516,444.83 | 93,479,909 | 72,005,586.17 | 40,332,596.67 |
| (一)基本每股收益 | 0.07 | 0.35 | 0.27 | 0.15 |
| (二)稀释每股收益 | 0.07 | 0.35 | 0.27 | 0.15 |
| 九、综合收益总额 | 18,516,444.83 | 93,479,909 | 72,005,586.17 | 40,332,596.67 |
| 归属于母公司股东的综合收益总额 | 18,516,444.83 | 93,479,909 | 72,005,586.17 | 40,332,596.67 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-25 | 2023-08-02 |
| 审计意见(境内) | | 标准无保留意见 | | |